The overall goal of our research is to understand the cellular and molecular mechanisms that contribute to the causes of bone cancer.
Cancer-induced bone disease is a characteristic feature of several types of cancer, including the hematological malignancy multiple myeloma, and other tumors that metastasise to bone such as breast, prostate and lung. In addition to the development of debilitating skeletal complications, the bone marrow provides a unique hospitable microenvironment, and once tumors become established in bone, they are largely unresponsive to treatment.
The overall goal of our research is to elucidate the cellular and molecular mechanisms that contribute to disease pathogenesis, and so identify and validate novel therapeutic approaches. Our focus is on the role of the tumor microenvironment and tumor-host interactions.
Kay Kendall Leukaemia Fund
Leukaemia and Lymphoma Research
Oxford Cancer Research Centre
University of Oxford Medical Research Fund
National Institute of Health / National Cancer Institute
FP7 — Marie Curie Career Integration Grant
Professor Freddie Hamdy
Dr Richard Bryant
Dr James Edwards
Professor Nick Athanasou
Dr Conor Lynch (Moffit Cancer Center, Florida, USA)
Dr Matthew Drake (Mayo Clinic, Rochester, USA)
Dr Florent Elefteriou (Vanderbilt University, Nashville, USA)
Researchers at Oxford University have launched a pioneering project to tackle crippling bone pain suffered by thousands of cancer patients.
Dr Emma Morris has been named as the first ever recipient of the annual Neil Mackenzie Public Engagement Award by the Bone Research Society (BRS).